McDermott Will & Emery has advised TreeFrog Therapeutics on the deal. TreeFrog Therapeutics, a French biotech company aiming to unlock access to cell therapies for millions...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Innate Pharma S.A. in this transaction. Innate Pharma S.A., a clinical-stage biotechnology company specializing in the development of cancer immunotherapies, has...
You must be a Standard 1 Year member to access this content.
McDermott advised Pierre Fabre in this transaction. The French pharmaceutical and dermo-cosmetic company, Pierre Fabre, has recently entered into an exclusive collaboration and licensing agreement with...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Innate Pharma on the deal. Innate Pharma announced the expansion of its collaboration with Sanofi. Sanofi is licensing a natural killer...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Corteria Pharmaceuticals on the deal. Corteria Pharmaceuticals, a French biotechnology company specializing in the development of interceptive therapies for heart failure...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Dynacure on the deal. Dynacure, a clinical-stage company focused on developing and commercializing innovative therapies to transform the lives of patients...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised Corlieve Therapeutics, while Morgan Lewis has advised uniQure on the deal. Corlieve Therapeutics completed its sale to uniQure, with its...
You must be a Standard 1 Year member to access this content.
IN BRIEF: McDermott Will & Emery, advised on the matter. McDermott Will & Emery advised Pierre Fabre S.A. with a team including Emmanuelle Trombe (Picture –...
You must be a Standard 1 Year member to access this content.
